Amgen and AstraZeneca report positive Phase III results for Tezspire in EoE

US stock index futures rose on Wednesday, with tech stocks expected to lead gains. SpaceX (SPCX) shares surged 8.8% after beating earnings estimates, while Super Micro Computer (SMCI) gained 12.2% on raised revenue outlook. Netflix (NFLX) fell 6.8% and AT&T (T) dropped 5% despite strong earnings. Investors await results from Tesla (TSLA), Meta (META), and IBM (IBM). Dow, S&P 500, and Nasdaq showed mixed performance on Tuesday.

AstraZeneca's Tezspire showed higher remission rates in eosinophilic esophagitis (EoE) patients than placebo in a phase 3 trial, with 67.8% and 63.3% remission for 210 mg and 420 mg doses, respectively, versus 5.4% for placebo. Both doses also improved swallowing scores. The trial enrolled 368 patients, and AstraZeneca plans to share findings with regulators.

Amgen and AstraZeneca reported positive Phase III trial results for Tezspire in treating eosinophilic oesophagitis, meeting primary endpoints. The study showed significant improvements in tissue remission and symptom reduction compared to placebo. Tezspire is already approved for severe asthma and chronic rhinosinusitis with nasal polyps in several regions. The companies plan to equally share costs and profits, with Amgen receiving a mid-single-digit royalty.

AstraZeneca and Amgen's Tezspire met co-primary endpoints in a Phase III trial for eosinophilic esophagitis, with 64.8% and 68.9% remission rates for 210 mg and 420 mg doses, respectively, vs. 3.5% for placebo. The companies plan to submit data to regulators for approval.

U.S. stocks closed mixed on Tuesday, with the Dow Jones rising 529.85 points, boosted by 3M's 5.82% gain after strong Q3 results and a deal with Amazon. 3M reported $6.6B in sales and raised its full-year EPS guidance. GM fell 6.84% despite beating expectations, citing narrowed full-year EBIT guidance. Health care and small caps outperformed, while tech stocks were mixed. SpaceX reported strong Q3 results, beating expectations.

Amgen and AstraZeneca reported Phase III results for Tezspire in treating eosinophilic esophagitis (EoE), planning regulatory discussions for potential approval. Tezspire is already FDA-approved for severe asthma and another indication, positioning it ahead of competitors in the TSLP drug class.